A Phase I, Open-label Clinical Study on Safety and Pharmacokinetics of SHR0410 Injection for Multiple Administration in Hemodialysis Patients
Latest Information Update: 22 Aug 2022
At a glance
- Drugs SHR-0410 (Primary)
- Indications Acute pain; Pruritus
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 17 Aug 2022 Status changed from active, no longer recruiting to completed.
- 21 May 2020 Planned End Date changed from 1 Nov 2019 to 28 May 2020.
- 21 May 2020 Status changed from recruiting to active, no longer recruiting.